Nayzilam Does NOT Cause False-Positive Barbiturate Screens
Nayzilam (midazolam) nasal spray will NOT cause a positive urine drug screen for barbiturates. Midazolam is a benzodiazepine, not a barbiturate, and these are distinct drug classes that are detected by separate immunoassay panels on urine drug screens.
Understanding the Drug Classes
Midazolam, the active ingredient in Nayzilam, is classified as a benzodiazepine - specifically a Schedule IV controlled substance 1. Barbiturates are an entirely different class of sedative-hypnotic medications with distinct chemical structures and metabolic pathways.
What Nayzilam WILL Show on Drug Screens
Nayzilam will test positive on benzodiazepine panels, not barbiturate panels. Research demonstrates that midazolam and its major metabolite (alpha-hydroxy midazolam glucuronide) are readily detected by benzodiazepine immunoassays 2. All three major benzodiazepine screening assays (EMIT, Abbott TDx, and Abbott ADx) successfully detected midazolam metabolites in urine specimens from treated patients 2.
Key Clinical Considerations
Cross-Reactivity Does Not Occur Between These Classes
The guideline literature on urine drug testing emphasizes that false-positive results occur within drug classes due to cross-reactivity, not between unrelated drug classes 3. For example:
- Fluoroquinolone antibiotics can cross-react with opiate screens
- Amphetamine medications can cross-react with amphetamine screens
- Diphenhydramine can cross-react with methadone screens 4
However, there are no documented cases of benzodiazepines causing false-positive barbiturate results.
Detection Window
Midazolam has a short half-life (1.5-3.5 hours) with less than 1% excreted unchanged 2. The major urinary metabolite (alpha-hydroxy midazolam glucuronide) remains detectable in benzodiazepine panels, but this detection is specific to benzodiazepine immunoassays, not barbiturate assays.
Important Pitfall to Avoid
Do not confuse benzodiazepine and barbiturate drug panels - they are separate tests on standard urine drug screens. If a patient using Nayzilam has a positive barbiturate screen, investigate for:
- Actual barbiturate use (phenobarbital, butalbital, secobarbital)
- Laboratory error
- Sample contamination or adulteration 3
The positive result is NOT from the Nayzilam.
Documentation Recommendation
When interpreting drug screens in patients prescribed Nayzilam, document the medication in the medical record to explain expected positive benzodiazepine results and avoid misinterpretation as substance abuse 3. However, this documentation is irrelevant to barbiturate testing, as no cross-reactivity exists.